Switch theme
Sign up to access all valuation multiples
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
2003
716
LTM Revenue $122M
LTM EBITDA -$18.8M
$290M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neuronetics has a last 12-month revenue (LTM) of $122M and a last 12-month EBITDA of -$18.8M.
In the most recent fiscal year, Neuronetics achieved revenue of $74.9M and an EBITDA of -$35.2M.
Neuronetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neuronetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $122M | XXX | $74.9M | XXX | XXX | XXX |
| Gross Profit | $66.2M | XXX | $54.2M | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | -$18.8M | XXX | -$35.2M | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | -47% | XXX | XXX | XXX |
| EBIT | -$31.5M | XXX | -$34.6M | XXX | XXX | XXX |
| EBIT Margin | -26% | XXX | -46% | XXX | XXX | XXX |
| Net Profit | -$39.7M | XXX | -$43.7M | XXX | XXX | XXX |
| Net Margin | -32% | XXX | -58% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $36.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Neuronetics's stock price is $3.
Neuronetics has current market cap of $221M, and EV of $290M.
See Neuronetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $290M | $221M | XXX | XXX | XXX | XXX | $-0.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Neuronetics has market cap of $221M and EV of $290M.
Neuronetics's trades at 3.9x EV/Revenue multiple, and -8.3x EV/EBITDA.
Equity research analysts estimate Neuronetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neuronetics has a P/E ratio of -5.6x.
See valuation multiples for Neuronetics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $221M | XXX | $221M | XXX | XXX | XXX |
| EV (current) | $290M | XXX | $290M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | -15.4x | XXX | -8.3x | XXX | XXX | XXX |
| EV/EBIT | -9.2x | XXX | -8.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.6x | XXX | -5.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeuronetics's last 12 month revenue growth is 32%
Neuronetics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Neuronetics's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neuronetics's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neuronetics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | -47% | XXX | XXX | XXX |
| EBITDA Growth | -30% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 0% | XXX | -15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neuronetics acquired XXX companies to date.
Last acquisition by Neuronetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Neuronetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Neuronetics founded? | Neuronetics was founded in 2003. |
| Where is Neuronetics headquartered? | Neuronetics is headquartered in United States of America. |
| How many employees does Neuronetics have? | As of today, Neuronetics has 716 employees. |
| Who is the CEO of Neuronetics? | Neuronetics's CEO is Mr. Keith J. Sullivan. |
| Is Neuronetics publicy listed? | Yes, Neuronetics is a public company listed on NAS. |
| What is the stock symbol of Neuronetics? | Neuronetics trades under STIM ticker. |
| When did Neuronetics go public? | Neuronetics went public in 2018. |
| Who are competitors of Neuronetics? | Similar companies to Neuronetics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Neuronetics? | Neuronetics's current market cap is $221M |
| What is the current revenue of Neuronetics? | Neuronetics's last 12 months revenue is $122M. |
| What is the current revenue growth of Neuronetics? | Neuronetics revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Neuronetics? | Current revenue multiple of Neuronetics is 2.4x. |
| Is Neuronetics profitable? | Yes, Neuronetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neuronetics? | Neuronetics's last 12 months EBITDA is -$18.8M. |
| What is Neuronetics's EBITDA margin? | Neuronetics's last 12 months EBITDA margin is -15%. |
| What is the current EV/EBITDA multiple of Neuronetics? | Current EBITDA multiple of Neuronetics is -15.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
